Boston Trust Walden Corp Has $30.09 Million Stock Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

Boston Trust Walden Corp cut its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 31.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 216,665 shares of the medical instruments supplier's stock after selling 100,581 shares during the quarter. Boston Trust Walden Corp owned about 0.88% of ICU Medical worth $30,086,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. SG Americas Securities LLC acquired a new stake in ICU Medical in the 1st quarter valued at about $859,000. Vanguard Group Inc. raised its position in ICU Medical by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 2,682,065 shares of the medical instruments supplier's stock valued at $416,176,000 after purchasing an additional 17,805 shares in the last quarter. Norges Bank acquired a new stake in ICU Medical in the 4th quarter valued at about $40,151,000. Proficio Capital Partners LLC acquired a new stake in ICU Medical in the 4th quarter valued at about $5,779,000. Finally, O Shaughnessy Asset Management LLC acquired a new stake in shares of ICU Medical during the 4th quarter worth about $249,000. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at ICU Medical

In other ICU Medical news, COO Christian B. Voigtlander sold 5,556 shares of the firm's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $138.65, for a total transaction of $770,339.40. Following the transaction, the chief operating officer now directly owns 2,389 shares in the company, valued at $331,234.85. This trade represents a 69.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Elisha W. Finney sold 600 shares of ICU Medical stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $138.92, for a total value of $83,352.00. Following the completion of the transaction, the director now owns 3,252 shares in the company, valued at $451,767.84. The trade was a 15.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 36,097 shares of company stock valued at $4,860,156. Insiders own 1.50% of the company's stock.

Wall Street Analyst Weigh In

ICUI has been the topic of several research analyst reports. Raymond James Financial cut their price target on ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating on the stock in a research report on Friday, May 9th. Needham & Company LLC reiterated a "hold" rating on shares of ICU Medical in a research note on Tuesday, April 8th. KeyCorp lowered their target price on ICU Medical from $209.00 to $191.00 and set an "overweight" rating on the stock in a research note on Monday, April 21st. Finally, Wall Street Zen upgraded ICU Medical from a "hold" rating to a "buy" rating in a research note on Sunday, May 18th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $192.67.

ICU Medical Price Performance

Shares of ICUI traded up $0.33 during trading hours on Monday, hitting $128.07. 134,916 shares of the company were exchanged, compared to its average volume of 271,888. The company has a market capitalization of $3.15 billion, a PE ratio of -33.44 and a beta of 0.88. The firm has a fifty day simple moving average of $134.70 and a 200-day simple moving average of $147.30. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.59 and a quick ratio of 1.52. ICU Medical, Inc. has a one year low of $111.97 and a one year high of $196.26.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 EPS for the quarter, topping the consensus estimate of $1.23 by $0.49. The business had revenue of $599.49 million during the quarter, compared to analysts' expectations of $574.15 million. ICU Medical had a positive return on equity of 6.75% and a negative net margin of 3.87%. ICU Medical's revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.96 earnings per share. As a group, sell-side analysts predict that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.